Atrial fibrillation and survival on a medical intensive care unit
- PMID: 38141732
- DOI: 10.1016/j.ijcard.2023.131673
Atrial fibrillation and survival on a medical intensive care unit
Abstract
Background: Atrial fibrillation (AF) is common among patients in the intensive care unit (ICU) and can be triggered by severe illness or preexisting conditions. It is debated if AF is an independent predictor of poor outcome.
Methods: Data derives from a single center retrospective registry including all patients with a stay on the medical ICU for >24 h. The primary endpoint was ICU survival. Secondary endpoints included receiving mechanical support (renal, respiratory or circulatory), hemodynamic parameters during AF, rate and rhythm control strategies, anticoagulation, and documentation.
Results: A total of 616 patients (male gender 62.3%, median age 75 years) were included in our analysis. New-onset AF was diagnosed in 87 patients (14.1%), 136 (22.1%) presented with preexisting AF, and 393 (63.8%) did not develop AF. Initial episodes of new-onset AF exhibited higher hemodynamic instability than episodes in preexisting cases, with elevated heart rates and increased catecholamine doses (both p < 0.001). ICU survival in new-onset AF was 80.5% (70/87) compared to 92.4% (363/393) in patients without AF (OR 0.340, CI 0.182-0.658, p < 0.001). Likewise, ICU survival in preexisting AF was 86.8% (118/136) was significantly lower compared to no AF (OR 0.542, CI 0.290-0.986, p = 0.050*). Independent predictors of ICU survival for patients were atrial fibrillation (p = 0.016), resuscitation before or during ICU stay (p < 0.001), and receiving acute dialysis on ICU (p = 0.002).
Conclusions: ICU survival is noticeably lower in patients with new-onset or preexisting atrial fibrillation compared to those without. Patients who develop new-onset AF during their ICU stay warrant special attention for both short-term and long-term care strategies.
Keywords: Arrhythmia; Atrial fibrillation; ICU; Shock; Survival.
Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest AS reports research grants and lecture fees from CytoSorbents and lecture fees from Abiomed, both outside the submitted work. TWengenmayer reports lecture fees from OrionPharma, GetingeGroup, Medtronic, AstraZeneca, and Novartis all of which are outside the submitted work. DLS reports lecture fees from Abiomed, OrionPharma, GetingeGroup, Medtronic, AstraZeneca, and Dahlhausen all of which are outside the submitted work. The other authors declare that they have no competing interests.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
